Pharmaceutical giant Eli Lilly announced it would refund 340B providers for overcharges of certain dosages of its brand-name insulin Humulin.

Lilly Posts 340B Refund Notice for Insulin Product Humulin

Drug manufacturer Eli Lilly announced a new round of refunds for Humulin, a brand-name insulin, following a 340B ceiling price [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.